Pomerantz Law Firm Investigates Investor Claims Against Neurogene Inc. Amid Securities Fraud Allegations
Pomerantz Law Firm's Investigation into Neurogene Inc.
Pomerantz LLP, a well-regarded law firm known for its expertise in securities class action litigation, is currently investigating claims on behalf of investors of Neurogene Inc. This investigation addresses concerns about the company’s potential involvement in securities fraud or other illegal business practices.
Background on Neurogene Inc.
Neurogene Inc. (NASDAQ: NGNE) is a biotech company focused on developing gene therapies for rare neurological disorders. However, their recent press releases have raised alarm among investors regarding both the safety of their treatments and the integrity of the company's disclosures. On November 11, 2024, Neurogene published interim clinical results from an ongoing Phase 1/2 trial centered on NGN-401, a gene therapy intended for pediatric patients suffering from Rett syndrome. Although touted as
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.